Detail akcie Exelixis online

Business Summary: Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Financial Summary: BRIEF: For the fiscal year ended 29 December 2023, Exelixis Inc revenues increased 14% to $1.83B. Net income increased 14% to $207.8M. Revenues reflect CABOMETYX segment increase of 17% to $1.61B, License revenues segment increase of 10% to $178.6M, U.S segment increase of 16% to $1.65B, Japan segment increase of 37% to $39.5M. Net income also reflects Interest Income increase from $33.1M to $86.5M (income).